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138Clinical outcomes and cost-effectiveness of initial
treatment strategies for nonembolic acute limb
ischemia in real-life clinical settings
Fedor Lurie, MD, PhD,a Varun Vaidya, PhD,b and Anthony J. Comerota, MD,a Toledo, Ohio
Objective: The optimal initial treatment for patients with acute limb ischemia (ALI) remains undeﬁned. Although clinical
outcome data are inconsistent, catheter-directed thrombolysis (CDT) with tissue plasminogen activator is increasingly used.
Patient-level analysis combining clinical and economic data in a real-life setting is lacking. This study compared clinical
outcomes and cost-effectiveness of initial treatment strategies for nonembolic ALI using real-life patient-level data.
Methods: Medical records and data for hospital costs were analyzed for nonembolic ALI patients treated in four hospitals
over 3 years. A cost-effectiveness analysis was performed using a decision tree analytic model. All costs were valued based
on cost-to-charge ratios.
Results: In 205 patients, initial treatments were CDT alone in 68 or with angioplasty in 16, open surgery in 60, endo-
vascular in 33, and hybrid in 28. Although clinical outcomes did not differ signiﬁcantly among the groups, reintervention
rates during hospital stay, readmission rates, and costs were highest in the CDT group. Reintervention was required in
62% of patients after CDT compared with 7% after open surgery, and 16% of the CDT patients needed more than one
reintervention. The mean total hospital cost was $34,800 per patient in CDT group compared with $10,677 in open
surgery group.
Conclusions: In this real-life study, initial treatment of nonembolic ALI with currently available CDT options was
associated with greater health care resource consumption and cost compared with other initial treatment options. (J Vasc
Surg 2015;61:138-46.)Acute limb ischemia (ALI) is associated with high
morbidity and mortality, which is underappreciated by
health care providers and researchers.1 A persistent ques-
tion is the proper choice of the initial treatment of patients
with ALI, which remains undeﬁned despite considerable
efforts to answer this question.2
The contemporary economic climate increasingly re-
quires health care providers to include cost considerations
in management decisions. Merging these considerations
with evidence-based recommendations may be chal-
lenging, especially when multiple interventions competing
for the same clinical indication have similar outcomes and
no deﬁnitive evidence is available. An important dimension
of this challenge is that most of the evidence-based recom-
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Clinical reality, however, is heterogeneous in nature,3 and
translating such evidence into real-world community prac-
tice is often difﬁcult.
Variability of response to intervention, clinician treat-
ment preferences, and the particular health care environ-
ment may result in different outcomes and costs in
community practices than those expected from meta-
analyses of RCTs.4,5 Moreover, the commonly reported
outcomes of these RCTs, such as amputation-free survival
(AFS) and primary, primary assisted, and secondary patency
of the treated vessel, do not reﬂect the cost of the treat-
ment. The availability of real-world community data that
analyze the outcome and cost of interventions helps to
delineate these differences and develop strategies to
improve clinical and ﬁnancial outcomes.
Generating data for the treatment of ALI is chal-
lenging. Administrative databases, such as the National
Hospital Discharge Survey, have been used6,7 but have sig-
niﬁcant limitations for the analysis of ALI outcomes and
cost. A validation study showed low speciﬁcity and positive
predictive value of the diagnostic codes typically used in
ALI analyses.7 However, diagnostic codes do not differen-
tiate between ALI vs worsening of chronic limb ischemia or
between embolic and nonembolic ALI, making estimations
of incidence, in-hospital costs, and mortality unreliable.7,8
Single-center studies of ALI have demonstrated that
outcomes of interventions can differ signiﬁcantly from
those reported in RCTs.6 Composition of the patient
Fig 1. Diagram illustrates the patient selection process. CDT, Catheter-directed thrombolysis; CDTA, catheter-
directed thrombolysis with angioplasty; EV, endovascular; HT, hybrid treatment; OS, open surgery.
JOURNAL OF VASCULAR SURGERY
Volume 61, Number 1 Lurie et al 139population is a contributing factor for such a difference.
Subset analyses of the RCTs showed differences in out-
comes of interventions in embolic and nonembolic ALI,
proximal and distal occlusions, and occlusions of a native
vessel or bypass graft.9,10
To more accurately ascertain the outcomes and associ-
ated cost of treating ALI in a real-world situation, we
analyzed the medical records of a representative sample
of patients treated for ALI by physicians of different spe-
cialties who are not connected by common administrative
and practice guidelines.
METHODS
The medical records of all patients (n ¼ 1074)
admitted to four ProMedica community hospitals with a
primary diagnosis of acute or chronic limb ischemia from
January 2009 to December 2012 were collected (Fig 1).
The Institutional Review Board approved the protocol,
data collection tool, and study design, with the understand-
ing that informed consent was not required due to the
study’s retrospective nature.
Patients admitted for elective treatment and those who
did not undergo invasive treatment were excluded, result-
ing in 841 patients. Of these, only patients treated
#14 days of onset of their symptoms of nonembolic ALI
were included in the ﬁnal analysis. Ischemia was considered
embolic if the patient had arrhythmia, a history of arterial
embolism, sudden onset of symptoms, characteristicangiographic appearance, and when open surgical treat-
ment was performed based on the macroscopic appearance
of embolus. Two vascular surgeons not participating in the
study independently reviewed 38 patients who did not have
clearly deﬁned inclusion criteria in their records and
excluded 17 additional patients with embolic ALI.
The study included 205 patients with nonembolic ALI
who were divided into ﬁve groups by the initial treatment
option:
d Group 1 included 68 patients initially treated with
catheter-directed thrombolysis (CDT) and in whom
no other intervention was performed #24 hours.
d Group 2 had 16 patients in whom the underlying lesion
was found and treated with CDT and then with angio-
plasty (CDTA) #24 hours after CDT completion.
d Group 3 included 60 patients initially treated with
open surgery, including operative thrombectomy, end-
arterectomy, patch angioplasty, bypass, or any combi-
nation thereof.
d Group 4 had 33 patients initially treated with endovas-
cular procedures, including atherectomy, balloon an-
gioplasty, thrombectomy with AngioJet (Medrad,
Warrendale, Pa), stenting, or a combination of these,
in which postprocedure CDT was not used.
d Group 5 included 28 patients in whom a hybrid com-
bination of open and endovascular techniques were
used.
Table I. Patient demographics, comorbidities, and severity of ischemia
Treatment group No.
Gender, No. (%) Age, years Comorbidities, No. ALI class, No. (%)
Male Female Mean SD Mean SD I IIa IIb III
CDT 68 46 (68) 22 (32) 68.6 12.4 3.5 1.5 0 61 (90) 3 (4) 4 (6)
CDTA 16 6 (38) 10 (62) 69.2 13.6 2.9 1.8 0 14 (88) 1 (6) 1 (6)
Open surgery 60 35 (58) 25 (42) 66.7 13.9 3.2 1.5 1 (1) 52 (87) 4 (7) 3 (5)
Endovascular 33 18 (54) 15 (46) 69.9 14.9 3.3 1.9 0 31 (94) 1 (3) 1 (3)
Hybrid 28 20 (71) 8 (29) 65.6 12.4 2.9 1.4 0 24 (86) 2 (7) 2 (7)
P .14 .7 .6 .98
ALI, Acute limb ischemia; CDT, catheter-directed thrombolysis; CDTA, catheter-directed thrombolysis and angioplasty; SD, standard deviation.
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ities, medications taken before admission, and smoking
status were collected for all patients. Severity of ischemia
was graded according to Society for Vascular Surgery
reporting standards.11 Anatomic location of the
occluded vessel was classiﬁed by arteriograms and duplex
ultrasound imaging.
Outcome measures. Clinical and technical outcomes
were assessed. The number and type of reinterventions,
complications, relief of ischemia, limb salvage, and AFS
at discharge were recorded. Primary success was deﬁned
as clinical improvement of ischemia to the level that did
not require further intervention during the hospital stay.
Limb salvage was deﬁned as the patient being discharged
without amputation proximal to the ankle. Major
bleeding events were deﬁned as those that contributed
to death, resulted in hemodynamic compromise, intracra-
nial hemorrhage, or intervention, or required blood trans-
fusion. Consumption of health care resources included
the length of stay (LOS) during the initial hospitalization,
the LOS in the intensive care unit (ICU), time from
admission to the primary intervention, and time between
the initial hospitalization and reinterventions. Because the
focus of the analysis was the cost of treatment to the hos-
pital, readmission #30 days from the hospital discharge
was also included.
Cost calculation. Cost calculations used center-
speciﬁc costs and hospital level cost-to-charge ratios to
accurately estimate the cost of care for each patient. The
cost of invasive procedures was separated from the cost of
supplies, implants, and devices used during the procedure.
Costs of tissue plasminogen activator (tPA) and all anti-
coagulants were analyzed as separate variables from overall
medication costs. Costs of readmission were calculated
based on the same components as the costs of the initial
hospitalization.
Statistical analysis. Normally distributed continuous
variables are expressed as means and standard deviations,
and categoric variables are expressed as percentages. Uni-
variate analyses were initially done to examine the rela-
tionships among outcome variables and patient-related
variables (sex, age, smoking, ALI class, affected vessel) to
identify potential differences among the treatmentgroups and to examine relationships among costs and
other variables. Multivariate analysis included binominal
and multinomial logistic regression models for categoric
outcome variables, and the generalized linear model was
used for continuous outcome variables. Calculations
were done using SPSS 19.0 software (IBM Corp,
Armonk, NY). Variables that achieved a P # .150 in
univariate analyses were included in the multivariate
analysis models.
RESULTS
Patients were predominantly male (61%), with a mean
age of 67.9 6 13.3 years (range, 30-97 years), and 46%
were smokers, with an equal proportion among men
and women. At the time of admission, 81 patients
(39.5%) were taking clopidogrel, 102 (49.8%) were taking
aspirin, and 70 (34.1%) were receiving Coumadin (Bris-
tol-Myers Squibb, Princeton, NJ) therapy. Arterial hyper-
tension was the most frequent comorbid condition,
present in 179 patients (87.3%), followed by coronary
artery disease in 70, diabetes in 63, chronic obstructive
pulmonary disease in 40, and chronic kidney disease in
32. Chronic peripheral arterial disease was present in 42
patients (20.5%).
The cause of ALI was an occluded native vessel in 115
patients (56.1%) and an occluded bypass graft in 90
(43.9%). The site of occlusion was proximal to the popliteal
artery in 81 patients (39.5%) and in the popliteal artery or
more distal in 124 (60.5%). At the time of admission,
ischemia severity was class IIa in 182 patients (88.8%), class
IIb in 11, class III in 11, and class I in 1. There were no
demographic differences among the treatment groups
(Table I).
Multivariate analysis failed to show an association be-
tween the choice of initial treatment, patient characteristics
(eg, age, gender, current medications, presence of speciﬁc
comorbidities or number of comorbidities), location of
the occlusion, or the class of ischemia, individually or in
combination. The only exception was that patients with
bypass graft occlusions were more likely to be treated
initially with CDT or CDTA than with other surgical op-
tions. Seventy-three percent of patients with occlusion of
a native vessel were treated with open surgery or an
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Fig 2. Patient management trajectories during the initial hospital stay and readmissions #30 days from hospital
discharge. ALI, Acute limb ischemia; CDT, catheter-directed thrombolysis; CDTA, catheter-directed thrombolysis
with angioplasty; EV, endovascular; HT, hybrid treatment; OS, open surgery.
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patients with occluded bypass graft (risk-adjusted odds
ratio [OR], 3.9; 95% conﬁdence interval [CI], 2.2-7.0).
The total dose of tPA was 36.7 6 15.2 mg in the CDT
group and 33.7 6 18.8 mg in the CDTA group.
Initial treatment resulted in an overall primary suc-
cess of 67.3%. Sixty patients (29.7%) required a second
intervention, 11 (5.4%) required a third intervention,
5 (2.4%) required amputation, and 2 (1%) died. The sec-
ond intervention was successful in 47 of 60 patients
(78.3%), two required amputation, and 11 required a
third intervention, all of which were successful (Fig 2).
The time from the initial treatment to reintervention
was 2.1 6 1.8 days (range, 1-8 days); 22 reinterventions
were done #48 hours and 10 #36 hours. Most of the
reinterventions were performed in the CDT group,
where 42 (62%) required additional procedures. The
AFS rate at discharge was 94% in the CDT group,
87.5% in the CDTA group, 95% in the open surgery
group, and 100% in the endovascular and hybrid groups.Complication rates did not differ among the treatment
groups (Table II).
In the entire study population, multivariate analysis
identiﬁed two predictors of AFS at discharge: ischemia
class <IIb (OR, 42.2; 95% CI, 8.1-221.5) and native
vessel occlusion (OR, 4.7; 95% CI, 2.1-23.3). However,
only the degree of ischemia was a predictor of AFS in
the CDT (OR, 45; 95% CI, 3.7-536.9) and open sur-
gery (OR, 14; 95% CI, 5.5-36.7) groups, and no predic-
tors were found in the other treatment groups. AFS rates
were not different between graft and native vessel
occlusions.
Readmission. Within 30 days of discharge, 32 patients
were readmitted to the hospital. The reason for readmis-
sion in 24 patients (75%) was related to their ALI treat-
ment. The reason for readmission was reocclusion of the
treated vessel in eight patients (25%), wound infection in
six (18.8%), and hematoma in three (9.4%). Two patients
required an amputation after readmission. The highest
rate of readmission was in the CDT and CDTA groups.
Table II. Mortality and complications
Treatment
group No.
Mortality,
No. (%)
Major
bleeding,
No. (%)
All complications,
No. (%)
CDT 68 0.0 2 (3) 27 (40)
CDTA 16 1 (6) 1 (6) 6 (38)
Open surgery 60 1 (2) 1 (2) 40 (24)
Endovascular 33 0.0 0.0 20 (61)
Hybrid 28 0.0 0.0 13 (46)
P .5 .7 .7
CDT, Catheter directed thrombolysis; CDTA, catheter directed throm-
bolysis with angioplasty.
Table III. Amputation-free survival (AFS) and
composite outcome of amputation and readmission-free
survival in patients treated for nonembolic acute limb
ischemia (ALI)
Treatment group No.
AFS,
No. (%)
AFS and readmission-free
survival, No. (%)
CDT 68 64 (94) 50 (74)
CDTA 16 14 (88) 10 (63)
Open surgery 60 57 (95) 52 (87)
Endovascular 33 33 (100) 30 (91)
Hybrid 28 28 (100) 25 (89)
P .2 .03
CDT, Catheter-directed thrombolysis; CDTA, catheter-directed throm-
bolysis with angioplasty.
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groups were related to the initial ALI episode compared
with seven (6%) patients from all other groups. Multivariate
analysis conﬁrmed that the higher rate of readmission in
these groups was related to the initial treatment indepen-
dent of other risks factors, including age, smoking, ALI
class, or occluded vessel (OR, 3.4; 95% CI, 1.5-7.4; P ¼
.003). Although the AFS rate upon discharge from the
initial hospitalization was not different among the groups,
the combined end point of readmission and AFS was signif-
icantly lower in the CDT and CDTA groups (Table III).
Cost factors: LOS and ICU. The LOS was the major
contributor to the total cost of hospitalization. On average,
43% of the overall cost was attributed to the hospital stay
(including ICU), 23% to the cost of the procedure, and
13% to supplies excluding medications. Regression analysis
showed 67% of variance in total cost was explained by vari-
ance in LOS and 43% by variance in ICU stay (Figs 2 and
3). Each additional day in the ICU increased the cost by an
average of $4414 (standard error, $374.30; P <
.0000001), and each additional day of hospital stay
increased costs by $2825 (standard error, 138.30; P <
.0000001).
Although the relative contribution of hospital stay
excluding ICU was not different among the groups,
the ICU portion of the overall stay and the percentage
of the total cost attributed to the ICU were highest in
the CDT and CDTA groups and lowest in the endovas-
cular group (Table IV). Multivariate analysis conﬁrmed
that with risk adjustment, the difference in ICU cost
was signiﬁcantly different among the groups (P ¼
.001). Post hoc analysis showed that the ICU cost in
the CDT group was higher than in the open surgery
group (P ¼ .012), whereas no differences were found
among the other groups.
Cost factors: treatment costs and readmissions. The
cost of treatment, which included the cost of the proce-
dure, supplies (catheters, stents), and tPA, was lowest for
the open surgery group. The relative contribution of the
treatment cost to the total cost of the initial hospitalization
was similar among the groups, except for the endovascular
group, in which it was signiﬁcantly higher (Table V). The
number of reinterventions increased both treatment andhospitalization costs. This was true for all treatment groups
and especially for the CDT group, which had the most
reinterventions (Table VI).
Composition of the treatment cost was expectedly
different among the groups. In the CDT and CDTA
groups, 14% of the cost on average was attributed to
tPA. The cost of supplies was the highest in the endovascu-
lar group, at 28% compared with 8% in CDT group and 7%
in the open surgical group (P < .0001). Procedure-related
costs were higher in the surgical groups, at 31% in the
open, 26% in the endovascular, and 26% in the hybrid
groups compared with 15% in the CDT and 18% in the
CDTA groups (P < .001).
The relative contribution of treatment-associated costs
to overall costs was similar regardless of the number of rein-
terventions, due primarily to the simultaneously increased
LOS. The correlation between the number of reinterven-
tions and LOS was rather weak but statistically signiﬁcant
(r ¼ .25, P < .0001 for all groups; r ¼ .31, P ¼ .01 for
the CDT group). Including readmission costs did not
change the relationship among treatment groups, with
the CDT and CDTA groups remaining the most expensive
(Table VII).
Patients in whom patency of the target vessel was
achieved had expectedly better economic outcomes. Their
LOS was 6.2 6 5.6 days compared with 10.5 6 6.9 days
for all other patients (P < .0001). ICU stay was 2.3 6
1.9 days compared with 5.3 6 4.2 (P < .0001). The cost
of the initial hospitalization was $18,403 6 $15,113
compared with $34,860 6 $29,218 (P < .0001). Even
when the cost of readmission was included, the total cost
remained signiﬁcantly lower at $20,212 6 $16,536
compared with $38,039 6 $33,783 in all other patients
(P < .0001). However, our analysis failed to reveal any pa-
tient characteristic or combination thereof that could be
used to predict procedural success.
DISCUSSION
The current health care environment demands
consideration of economic aspects of care in addition to
clinical outcomes. At least two factors make such
Fig 3. Relationship between the cost of the initial hospitalization and (A) the length of stay (LOS) and (B) days in the
intensive care unit (ICU).
Table IV. Days in the intensive care unit (ICU) and the hospital length of stay (LOS) and their effect on cost
Treatment group
ICU, days LOS, days ICU % of LOS ICU costa ICU % of total cost
Mean SD Mean SD Mean SD Mean SD Mean SD
CDT 5.1 4.1 9.7 6.3 52 18 7224 6086 24 10
CDTA 3.9 1.9 8.4 6.9 60 27 5653 2680 23 7
Open surgery 2.5 1.9 6.3 4.4 47 30 3295 2295 19 9
Endovascular 1.5 2.5 5.3 8.3 21 29 4031 3003 14 8
Hybrid 2.1 1.6 7.4 6.6 39 29 3741 1833 19 7
P <.0001 .008 <.0001 <0.001 <.0001
CDT, Catheter-directed thrombolysis; CDTA, catheter-directed thrombolysis with angioplasty; SD, standard deviation.
aCosts are shown in 2012 United States dollars.
Table V. Treatment cost in 2012 United States dollars
Treatment group
Initial hospitalization total cost Treatment cost Treatment % of total cost
Mean SD Mean SD Mean SD
CDT 31,606 28,750 9482 4251 36 12
CDTA 26,449 17,411 9053 3722 39 12
Open surgery 17,207 9,432 5852 3028 37 13
Endovascular 20,645 27,459 8298 5657 55 24
Hybrid 21,275 119,750 8121 3132 43 16
P .004 <.0001 <.0001
CDT, Catheter-directed thrombolysis; CDTA, catheter-directed thrombolysis with angioplasty; SD, standard deviation.
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logic and real-world data currently available are derived
from administrative databases and thus do not discrimi-
nate between acute and chronic ischemia and between
embolic and nonembolic ALI. Moreover, these databases
are nonspeciﬁc for major factors that determine clinical
outcomes of treatment such as degree of ischemia orthe affected vessel7 The second factor is that RCTs
although providing information for clinical efﬁcacy, do
not include cost and cannot be generalized to estimate
clinical efﬁciency in real-world settings. This study ad-
dresses an important gap in the current data by providing
cost information for a deﬁned clinical population in the
real-world setting.
Table VI. Effect of reinterventions on the costa
Reinterventions
Initial hospitalization
total cost Treatment cost
Treatment % of
total cost LOS, days
Mean SD Mean SD Mean SD Mean SD
All patients
0 19,546 16,193 6877 3282 42 18 6.60 6.2
1 29,890 23,509 9940 4998 38 12 9.30 6.9
$2 44,846 41,703 12,790 4748 37 14 11.40 5.3
P <.0001 <.0001 .26 .002
CDT group
0 21,610 9686 7716 3183 37 11 7 3
1 31,673 27,226 9033 3561 35 13 10 8
$2 50,035 44,434 13,659 4677 36 13 12 5
P .01 <.0001 .74 .04
CDT, Catheter-directed thrombolysis; LOS, length of stay; SD, standard deviation.
aCosts are shown in 2012 United States dollars. The number of reinterventions increases the cost of treatment and the cost of hospitalization. This was true for
all treatment groups and especially for the CDT group, which had the most reinterventions.
Table VII. Cost of initial hospitalization and cost
including 30-day readmissionsa
Treatment group
Initial hospitalization
total cost
Cost including
readmission
Mean SE Mean SE
CDT 31,606 28,750 34,800 31,299
CDTA 26,449 17,411 35,576 32,785
Open surgery 17,207 9432 18,015 10,677
Endovascular 20,645 27,459 21,788 27,389
Hybrid 21,274 11,975 21,732 12,102
P .004 .001
CDT, Catheter-directed thrombolysis; CDTA, catheter-directed throm-
bolysis with angioplasty; SE, standard error.
aCosts are shown are in 2012 United States dollars.
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criteria and adjudication process ensured greater accuracy
compared with using administrative data and made possible
the selection of only patients with nonembolic ALI
(deﬁned as #14 days between the onset of symptoms
and the time of admission). The Surgery vs Thrombolysis
for Ischemia of the Lower Extremity (STILE) trial12
conclusively showed that extending the time criteria
>14 days results in signiﬁcantly different treatment out-
comes. A comparison of the results of the STILE and
Thrombolysis or Peripheral Arterial Surgery (TOPAS)13
trials suggests a difference in thrombolytic outcomes be-
tween patients with embolic and nonembolic ischemia.
This was well established before in the vascular surgery
literature.14
Patients in this study were drawn from four com-
munity hospitals of the major health care system in
northwest Ohio (1477 acute care beds), which is a
representative population of nonembolic ALI patients.
Demographics of the study patients were similar to
those entered into RCTs9,10,13 and administrative
database studies,6,7 as were the proportion of smokersand the prevalence of major comorbidities such as
arterial hypertension, diabetes, coronary artery disease,
chronic obstructive pulmonary disease, and chronic
kidney disease. The anatomic location of the occluded
artery and proportion of native artery and graft occlu-
sions were also similar (45.9% of native artery occlu-
sions in this study, 45% in TOPAS). In contrast to
the RCTs, this patient population was treated exclu-
sively in nonacademic settings by private and
hospital-employed physicians of different specialties,
reﬂecting the real-world settings where most patients
receive care. Preference in selection of initial treat-
ment was clear in the patients with bypass graft occlu-
sions. Those patients were almost four times as likely
to be treated with CDT than with open surgery,
which is consistent with the strategy suggested by a
RCT.9,10 In summary, this study is likely to represent
the real-world practice of treating patients with non-
embolic ALI, and the differences in outcomes are
likely to reﬂect differences in practice patterns, physi-
cian choices, and hospital logistics rather than the dif-
ferences in patient populations.
The retrospective design is one of the limitations of
this study. However, because all studied variables were
available for all included patients, the data collection
may be viewed as not signiﬁcantly different from a pro-
spective registry.
Another limitation is the clinical deﬁnition of non-
embolic ischemia. Differentiation between embolic and
nonembolic ischemia is impossible in some cases. How-
ever, excluding patients with highly likely or obvious em-
bolism, which would be more likely treated with
modalities other than thrombolysis, was necessary for
an appropriate comparison among all of the initial treat-
ment strategies. The ﬁnding that patients with native
vessel occlusion were equally likely to be treated by
each of the treatment modalities indicates that the pres-
ence of embolic ischemia in studied patient population
was negligible.
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groups and comparable with published data. AFS at
discharge was 94% in the CDT group and 95% in the
open surgery group. TOPAS reported a 30-day AFS
rate of 83.5% for CDT and 88.6% for open surgery,13
and STILE reported 90.8% and 88.8%, respectively.12
The University of Michigan group reported an overall
rate (CDT and open surgery) of 74.3%.6 These results
may be partly explained by the high proportion of pa-
tients with grade IIa ischemia, which was a predictor
for AFS in the CDT and open surgery groups.
From the cost perspective, however, these outcomes
should be considered in conjunction with the primary
success rate, the frequency of reinterventions during the
hospital stay, and the frequency of relevant readmissions.
Most reinterventions and all multiple reinterventions
were performed in the CDT group, and the highest
readmission rate was in the CDT and CDTA groups.
Reinterventions were performed in 62% of CDT patients
in this study, which is within the 50% to 78% range re-
ported in the literature.10,15,16 The high rate of reinter-
vention may be due to late identiﬁcation or delayed
correction of residual abnormalities in thrombosed ves-
sels, or both. Although too small for statistical compari-
son, the CDTA group had only a 31% reintervention
rate. In addition to their direct cost, delayed reinterven-
tions prolonged LOS, which was the major contributor
to the hospital cost. It appears that correction of the un-
derlying lesion immediately after CDT may decrease
LOS and cost. Reinterventions, however, are just one
of many factors contributing to prolonged LOS. The
variability in hospital practice patterns and in administra-
tive processes is likely to play a signiﬁcant role in real-
world data.
Of particular concern is the long ICU stay in the
CDT and CDTA groups that is required by the nature
of the treatment. In the CDT group, however, 24% of
the cost of the initial hospitalization was attributed to
the ICU stay, which potentially can be decreased with
a safer and more effective lytic agent and lead to a sub-
stantial decrease in hospital cost. Another potential cost-
savings for the CDT and CDTA groups is decreasing the
volume or cost of tPA, which contributed 14% to the
cost of patient care. Similarly, supplies were the major
contributor to the total cost in the endovascular group.
Decreasing this cost may make endovascular treatment
the least expensive option. The cost of hospitalization
in the open surgery group was substantially determined
by the cost of the operative procedure itself, which
contributed 31% to the overall cost. A relatively short
ICU stay and the lower cost of other components of
care make it difﬁcult to identify other cost-saving strate-
gies in the open surgery group.
CONCLUSIONS
This cost-analysis suggests that strategies resulting in
fewer reinterventions and reduced LOS, such as a more
effective therapy and better patient selection, can decreasetreatment cost regardless of the choice of the initial treat-
ment. However, for CDT, these strategies may result in
greater cost-savings compared with other treatment
groups.
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sented, important topic. This area is obviously crying out for
some standardization and guidance, as it has been for the last
20 years, unfortunately. Do all your patients who undergo cath-
eter-directed thrombolysis go to the intensive care unit (ICU)
for monitoring, or do you have an intermediate stepdown area
for monitoring patients receiving thrombolytic therapy in a
lower-cost environment?
Dr Fedor Lurie. In the four hospitals included in the study,
all the patients go to the ICU. The cost of the interventional
unit was added to the ICU cost.
Dr Dalman. Because there are other options. I don’t know
that every patient needs to be in the ICU when they are receiving
catheter-directed thrombolysis.
So for the average patient now, based on these data, has this
changed your practice at all for the nonembolic acute limb
ischemia patients? Have you used these data to change your prac-
tice, or how are you currently managing those patients?
Dr Lurie. That is a key question. The data itself do not guide
us to change any speciﬁc aspect of our practice except to look at
the administrative policies that can affect the ICU stay, such as
inability to transfer patients from the ICU at certain times.
Dr Peter Henke (Ann Arbor, Mich). I agree with Ron, this
is really understudied and needs standardization, as was
mentioned.
But nonembolic acute limb ischemia can occur from a variety
of different etiologies. Can you give us an idea of what some of
those were. Were they just all acute-on-chronic peripheral arterial
disease (PAD), for example, or trauma, dissection, those type of
things? Because that may affect the management choice.Dr Lurie. One of the reasons we selected to study the patient
population that we have an access to the medical records was to
carefully select speciﬁc etiology. The majority of those patients
had a thrombotic ischemia, except ﬁve who had iatrogenic throm-
bosis. Twenty-one patients with thrombosis of a native artery had
clinical manifestation of PAD prior to acute ischemia, and 90 pa-
tients had thrombosis of a bypass graft. So I would think that
the results are mostly applicable for thrombotic ischemia in pa-
tients with or without PAD.
Dr John Blebea (Tulsa, Okla). Encompassing a multitude of
patients at four different hospitals, were you able to analyze and
deﬁne the selection of patients, and speciﬁcally, how was it decided
that these patients underwent surgery vs endovascular interven-
tions? Secondly, did you examine outcomes based on experience
or speciality of the physician for these procedures?
Dr Lurie. To address the second part, we did not do an anal-
ysis per provider. We can, but then we will end up with very small
numbers that will be unlikely meaningful.
Addressing the ﬁrst part of this question, I would like to
emphasize that the focus of this study is to look at what is
happening actually in the community settings. Patient selection
and decisions of which treatment modality to use as the initial op-
tion was done by community practitioners in the absence of insti-
tutional guidelines. The overall clinical outcomes were good. So
one can suspect that the selection of patients was appropriate.
One factor that I can tell you that we looked at, for example,
in the subgroup of patients with occluded grafts, thrombolysis was
used more frequently than other options, which is in line with the
recommendations of the Surgery vs Thrombolysis for Ischemia of
the Lower Extremity (STILE) trial.
